Cite
HARVARD Citation
Gounder, M. et al. (n.d.). Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas. European journal of cancer. pp. S3-S4. [Online].